Abstract.-This paper analyzes the impact of trans fat bans on cardiovascular disease (CVD) mortality rates. Several New York State jurisdictions have restricted the use of ingredients containing artificial trans fats in food service establishments. The resulting within-county variation over time and the differential timing of the policy's rollout is used in estimation. The results indicate that the policy caused a 4% reduction in CVD mortality rates, or 12 fewer CVD deaths per 100,000 persons per year. While the averted deaths can be valued at about $3.6 million per 100,000 persons annually, the costs associated with the policy are comparatively smaller.
I. Introduction
The medical community has reached a consensus on the link between the consumption of artificial trans fat and the risk of developing cardiovascular diseases (CVD) such as coronary heart disease (CHD).
Previous work has estimated that a 2% increase in energy intake from artificial trans fat increases the incidence of CHD by between 23% and 29% (Mozaffarian et al., 2006) . 1 In November 2013, the American Medical Association (AMA) indicated that a substitution away from oils containing artificial trans fats toward healthier options such as extra virgin olive oil could prevent 30,000 to 100,000 premature deaths each year. 2 Danaei et al. (2009) estimate that high trans fat consumption is responsible for about 82,000 CVDrelated deaths annually in the U.S.
The first major public policy response in the U.S. to the growing public health concern over trans fat consumption was in 2006 when the Food and Drug Administration (FDA) mandated trans fat labeling on packaged foods at the national level. The food industry reacted by reformulating its products to reduce the amount of trans fat contained in packaged foods (Unnevehr and Jagmanaite, 2008) . While recent work has documented a marked reduction in the amount of trans fat in the American diet (Doell et al., 2012) , an analysis of the health effects of a nationwide policy such as mandatory trans fat labeling is hampered by the absence of geographical policy variation and meaningful treatment and control units.
1 One gram of fat has 9 calories, so for an individual on a 2000-calorie daily diet this is approximately a 4.4g increase in trans fat consumption. In this paper, we contribute to the literature by analyzing whether there is a causal effect of artificial trans fat consumption on CVD-related mortality.
In particular, we evaluate a recent public policy response in some New York State (NYS) counties that mandated a substantial reduction in the amount of artificial trans fat in the local food supply. The policy, which is commonly referred to as a "trans fat ban", applies to all food service establishments that require a permit to prepare and serve food. The regulation imposes an upper limit on the amount of artificial or industrially produced trans fat allowed in food, which is generally 0.5g of trans fat per serving. Current estimates indicate that about one-third of daily calories come from food consumed outside the home (Lin and Guthrie, 2012) , so this policy has far-reaching implications for nutrition and health. 3 Between 2007 and 2011, trans fat bans were implemented by the health departments of six NYS counties and New
York City (NYC).
We use panel data on NYS county mortality rates for the [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] period. These data allow us to employ an empirical approach that controls for statewide time-varying determinants of mortality and permanent differences across counties. Trans fat bans and the resulting reductions in trans fat content in restaurant food were not randomly assigned across NYS counties. However, we make use of plausibly exogenous within-county variation over time in the artificial trans fat content in restaurant food resulting from the policy mandate and the differential timing of the policy's rollout to identify the CVD-related mortality effects of trans fat bans.
As Figure 1 illustrates, prior to the implementation of trans fat bans, both treated and control counties followed very similar downward-sloping trends in CVD mortality rates. While there are differences in mortality rates 3 In [2005] [2006] [2007] [2008] , about 20% of daily calories were consumed at restaurants and fast food outlets and 12% of daily calories were consumed at other establishments away from home (Lin and Guthrie, 2012) . Because most of the calories consumed away from home are from restaurants and fast food outlets, we often use the term "restaurants" to refer to the establishments targeted by the policy for ease of exposition.
between the treated and control counties, these differences are stable before the period in which trans fat bans were implemented. After the bans were implemented, we see a clear downward break in the trend in treated counties, and a relatively stable trend in control counties.
Note: Each county's trans fat ban implementation year is normalized to zero. Each point -4, -3,…, 4 corresponds to a mean for the control group that was taken over various years because of the variation in implementation years across treatment counties. For example, the control group mean at point 0 was taken over the years 2007, 2008, 2009, 2011, and 2012 , which correspond to the different implementation years of the treatment counties.
Our regression analysis indicates that mandating low upper limits on the content of artificial trans fat in restaurant food prevents a substantial number of CVD deaths. In particular, in our preferred specification, we find evidence indicating that implementation of a ban on the use of artificial trans fat in restaurants caused, on average, a 4% reduction in CVD mortality rates, which translates into a reduction of about 12 CVD-related deaths per 100,000 persons per year. An analysis of the impacts on the major components of CVD mortality reveals that trans fat bans reduce mortality caused by diseases of the heart by about 10 per 100,000 persons per year and reduce mortality due to cerebrovascular disease (stroke) by about 3 per 100,000 persons per year. Our results are robust to excluding NYC counties from the analysis, changes in the composition of the control group to address the potential for policy spillovers to neighboring counties and comparability concerns with treatment counties, a variety of changes in model specification, and addressing policy endogeneity concerns (e.g. hospital-level interventions in NYC counties to increase the accuracy of cause-of-death reporting and menu labeling laws).
Placebo analyses indicate that trans fat bans have much weaker impacts on mortality outcomes that are less likely or unlikely to be associated with the consumption of artificial trans fat. We also find evidence suggesting that the impact of trans fat bans on CVD-related mortality is concentrated among senior citizens who have, after all, the highest risk of mortality from CVD.
The analysis reveals that mortality caused by heart disease and stroke responds within a year to reductions in the amount of artificial trans fat in the local food supply. This is consistent with evidence from diet-related randomized control trials in the medical literature. For instance, the incidence of CVD-related events and mortality falls soon after individuals at high CVD risk switch to a Mediterranean diet and consume healthier fats (Estruch et al., 2013) . 4 Similarly, for individuals with CVD, the impact of statin therapy on low-density lipoprotein (LDL) cholesterol levels-the main channel through which trans fat consumption raises the risk of developing CVD-quickly reduces LDL cholesterol levels and CVD-related mortality risk (Law et al., 2003) . 5 Our results are also consistent with evidence in the economics 4 In a large randomized control trial in Spain, individuals with high CVD risk, but no CVD at baseline, were randomly assigned to be either (a) counseled to follow a Mediterranean diet and given extra-virgin olive oil or a mixture of nuts for free on a weekly basis, or (b) advised to reduce fat intake. The study found that the incidence of major CVD-related events including deaths responded quickly to an increased consumption of healthier fats (Estruch et al., 2013) . 5 In a meta-analysis of 164 randomized placebo-controlled trials with median duration of 8 weeks, Law et al. (2003) find that a daily intake of statins lowered LDL cholesterol levels by 1.8 mmol/l, and 58 randomized trials revealed that a 1 mmol/l reduction in LDL cholesterol resulted in an 11% reduction in fatal heart disease events in the first year.
literature that cardiovascular health is sensitive to changes in the environment or health-related behavior. For example, there is evidence that CVD-related mortality falls shortly after increases in cigarette taxes (Moore, 1996) , the implementation of smoke-free workplace laws (Adams et al., 2011) , changes in macroeconomic conditions (Ruhm, 2003) , and income receipt (Evans and Moore; 2011 , 2012 . In an analysis of the dynamics of the treatment effects, we provide evidence that, in addition to the effect on CVD-mortality occurring within one year, trans fat bans also have a lagged effect. This result gives reason to believe that the impact of the policy on prevented deaths or increased longevity may grow over time.
Heart disease is the leading cause of death in NYS, and we find that trans fat bans have the potential to lead to substantial reductions in the loss of life as a result of the consumption of artificial trans fat, which has no known health benefits. Given that the NYS counties that implemented trans fat bans over our study period had 34,215 heart-disease-related deaths in 2006, we estimate that, on average, implementation of trans fat bans prevented about 1,300 heart-disease-related deaths per year. Assuming a discount rate of 3%, Aldy and Viscusi (2008) find that the cohort-adjusted Value of a Statistical Life-Year is about $302,000. Even if fatal heart attacks cause only 1 year of life to be lost, the fatal heart attacks prevented by trans fat bans can be valued at about $393 million annually. In a cost-benefit analysis below, we calculate that these health benefits are likely to outweigh the costs to the food service industry and inconveniences to consumers.
The rest of the paper is organized as follows. First, we provide some background on the health effects of trans fat consumption and discuss related studies in the literature. Second, we describe the data used in the analysis.
Third, we outline the empirical strategy and discuss the main results. Fourth, we explore the heterogeneity of impacts across counties. Fifth, we explore the dynamics of the treatment effects. Sixth, we test for a variety of mechanisms that could underlie our results. Seventh, we discuss the magnitude and plausibility of our estimates and perform a rough cost-benefit analysis. Finally, we conclude.
II. Background and Previous Literature
There are two main sources of dietary trans fatty acids (trans fat) in the U.S. food supply. Natural trans fat occurs through biohydrogenation in ruminant animals and is found in meat and dairy products. However, Eckel et al. (2007) estimates that approximately 80% of the trans fat in the U.S. diet is artificial or industrially produced, and it is found in foods that contain partially hydrogenated oil (PHO). Artificial trans fat is created through a process called partial hydrogenation, whereby hydrogen gas is added to liquid vegetable oil, which converts it into semi-solid fat. Artificial trans fat is commonly used in the food production and service industries because it is less expensive than other fats, it increases the shelf life of products, and it may enhance the flavor and texture of food. Foods that typically contain artificial trans fat include shortenings, margarines, fried fast foods, baked goods, and snack foods (Eckel et al., 2007) .
Aside from its caloric value-which is the same as for all fats-there is no known health benefit of consuming artificial trans fats. The consumption of artificial trans fat raises levels of low-density lipoprotein (LDL), or "bad" cholesterol, and decreases high-density lipoprotein (HDL), or "good" cholesterol (Brouwer et al., 2010) . Thus, artificial trans fat consumption increases the total-to-HDL cholesterol ratio, which increases the risk of cardiovascular diseases (CVD) such as coronary heart disease (CHD). 6 Trans fat is generally considered worse than other fats (e.g. saturated fat) because, unlike other fats, it does not raise HDL cholesterol (Eckel et al., 2007) . 6 Consumption of saturated fat also increases the risk of heart disease, but to a much lesser extent than trans fat. A review by Ascherio et al. (1999) finds that a 2% increase in energy intake from industrially produced trans fat increases the LDL to HDL ratio by 0.1, which corresponds to a 5.3% increase in the risk of CHD; a 5% increase in energy intake from saturated fat is needed to result in the same increase in the risk of developing CHD.
Evidence from the epidemiology and medical communities indicates that adverse health effects are present at intake levels as low as 1 to 3% of total energy, which is only 20 to 60 calories for those on a 2000-calorie daily diet.
In contrast, there is comparatively less evidence to support a link between natural trans fat and the risk of developing CVD (Mozaffarian et al. 2006 ). Recent local legislation has addressed the fact that consumers are generally not able to determine the trans fat content in the foods that they consume away from home. The New York City (NYC) health department initially launched an education and awareness campaign to encourage restaurant owners to use oils free of artificial trans fat on a voluntary basis.
However, the campaign was found to be ineffective (Tan, 2009 ). The NYC 7 Mozaffarian et al. (2006) indicate that the lack of association between natural trans fat and heart disease risk "may be due to lower levels of intake (typically less than 0.5% of total energy intake), different biologic effects (ruminant and industrial trans fats share some, but not all, isomers), or the presence of other factors in dairy and meat products that balance any effects of the small amount of trans fats they contain."
health department deemed it appropriate after the failed campaign to regulate in restaurants and fast food establishments increased from 6% to 20%, while the share of daily calories consumed at home fell from 82% to 68%. Over the same time period, the share of total fat consumed on a daily basis provided by restaurants and fast food establishments increased from 7% to 23% (Lin and Guthrie, 2012) .
To the best of our knowledge, only a handful of studies have attempted to quantify the reduction in the amount of trans fat in restaurant food after the 10 It is important to note that trans fat bans do not fully eliminate the existence of trans fat in food away from home. As mentioned above, meat and dairy products contain naturally occurring trans fat, so it is virtually impossible to totally eliminate the presence of trans fat in restaurant food. Instead, these policies place a low upper limit on the amount of trans fat per serving of foods containing PHOs, shortenings, and margarines. In addition, these policies do not apply to packaged goods because they are under the jurisdiction of the FDA (Tan, 2009 ). Thus, pre-packaged potato chips or candy, for example, are permitted to be sold even if the trans fat content per serving is higher than 0.5g.
bans were implemented in restaurants. 11 Angell et al. (2009) show that in four major fast food chains in NYC, the amount of trans fat contained in French fries fell from an average of 4g before the ban to about 0.1g after the ban, or a reduction of about 98%. They also find that the amount of saturated fat in French fries decreased by about 10.5%. A more recent study analyzing transaction data from 11 NYC fast food chains found that, on average, trans fat per purchase fell by 2.4g and saturated fat increased by 0.55g after trans fat bans were implemented (Angell et al., 2012) ; however, the mean trans fat plus saturated fat content decreased by 1.9g. These studies are useful because they confirm that the policy was effective, i.e. that restaurants complied with the law and reduced the amount of trans fat in restaurant food, but it is important to note that they did not compare the change in the content of trans fat in fast food chains in NYC to chains in areas not subject to a ban. In addition, chains
are not necessarily representative of other food service establishments, so it is difficult to know the true size and distribution of the reduction in the amount of artificial trans fat in the local food supply of the counties that implemented the ban.
Nonetheless, the results in Agnell et al. (2009 Agnell et al. ( , 2012 point to substantial reductions in the amount of trans fat contained in restaurant food due to the bans and there is no evidence that restaurants make substitutions that fully offset these reductions with increases in saturated fat content, which also has adverse health effects. Moreover, as best as we can tell, there is no evidence that compliance with trans fat bans, which involves replacing trans- To complement our main analysis, we obtained comparable data for the NYS Metropolitan Area from the CDC Wonder Database, which we use to test the sensitivity of our results to changes in the composition of the control group.
The NYS Department of Health provided us with information on the effective dates of trans fat bans in restaurants for each county. 13 We verified this information by reviewing local laws from health department websites.
Appendix Table 1 shows the timing of trans fat bans in restaurants for each county that has implemented such a policy over the sample period. We 12 We define the sum of the mortality counts from "diseases of the heart" and "stroke" as the mortality attributable to CVD. The ICD-10 codes for diseases of the heart are I00-I09, I11, I13, and I20-I51; the ICD-10 codes for stroke are I60-I69.
consider a county to have a ban on trans fat if the law has been effective for at least 6 months in a given year. Notice that NYC and three other counties implemented their ban on trans fat over two phases. In some counties, some food service establishments were allowed to continue using oils and shortenings containing trans fat for deep frying cake batter and yeast dough until Phase II; however, the preparation of all other foods was affected by the policy in Phase I. If the ban was implemented over two phases, we use the earliest date of the ban. Later, we distinguish between the two Phases, and
show that the estimated impacts of the bans in Phase I and Phase II are similar. Table 1 shows county population-weighted summary statistics for the full sample and by whether a county implemented a ban on trans fat over the sample period. Averages over the sample period show that there were 288 CVD-related deaths per 100,000 persons, most of which are attributed to diseases of the heart. CVD-related deaths per 100,000 persons are lower (283) in the treatment counties than in the control counties (299). The number of deaths per 100,000 persons not attributable to CVD-to which we refer as net deaths-is also higher in the control counties (607) than in the treatment counties (419). However, CVD is responsible for a substantial share of deaths in both treatment (33%) and control (40%) counties. Economic conditions, as measured by unemployment rates and per capita personal income, are similar in the treated and control counties.
14 Appendix Table 2 shows additional summary statistics for the year 2006, the latest year before any county in our sample implemented a ban on trans fat in restaurants. Mortality caused by CVD was slightly higher in counties that implemented a ban over the study period relative to counties that did not. To examine the overall "healthiness" of counties that banned and did not ban trans fat over the study period, we obtained data on major CVD risk factors from the 2002-2012 waves of the Behavioral Risk Factor Surveillance System. 15 Counties that implemented a trans fat ban over the sample period were "healthier" in 2006 than other counties, as measured by lower rates of obesity, smoking, and drinking, but "less healthy" as measured by lower rates of physical activity. As we discuss in greater detail in the next section, so long as these differences across counties are fixed over time, our empirical model will account for them by controlling for county fixed effects in the regression analysis. Later, however, we also explore whether changes in health-related behaviors, which could be a component of the policy's impact on health, explain the reductions in CVD-related mortality.
IV. Empirical Analysis and Results

a. Empirical Model
To estimate the impact of trans fat bans on CVD mortality rates, we estimate the following model:
( 1) where M is the number of CVD-related deaths per 100,000 in county c in year t. TFB is a dummy variable equal to 1 if county c has implemented a ban on trans fat in year t, and zero otherwise. Time-varying county-specific factors that may affect mortality rates (e.g. unemployment rates) are grouped in matrix X. In order to account for unobservable county characteristics that may affect CVD mortality rates and are fixed over time, we control for a county fixed effect (γ c ). A county fixed effect would, for example, net out from the model differences in mortality that result from differences in the accuracy of cause-of-death reporting across counties, so long as these differences are time-constant and time-varying, that might affect mortality rates and whether a county implements health-related policies such as a ban on trans fat in restaurants. However, there remains the concern that counties may implement several policies around the same time that affect mortality rates, which makes it difficult for the analyst to isolate the impact of a single policy.
An important concern for policy endogeneity that we account for is that the NYC health department implemented interventions in some hospitals with the goal of reducing the over-reporting of deaths caused by heart disease.
The first hospital-level intervention was conducted between July and 12 additional hospitals across all 5 NYC counties in 2011 and 2012, yielding similar results .
It is important to note that the timing of these interventions does not coincide with the timing of trans fat bans in NYC, but they may cause us to overestimate the impact of trans fat bans on CVD mortality rates. Thus, as we discuss in greater detail below, we also include in matrix X a dummy variable for NYC interacted with a dummy variable equal to one for the years 2010-2012 to account for the structural break in NYC mortality rates as a result of the hospital-level interventions that occurred over this period. Two alternative strategies, which we describe in greater detail below, are (1) to drop counties in years that coincide with the hospital intervention or (2) to drop all observations from NYC. We find that both analyses produce similar results.
b. Main Results
In Table 2 , we present our main results, which reveal strong evidence that bans on artificial trans fat led to a sizeable and statistically significant decline in CVD mortality rates. We begin by estimating a stripped-down version of equation (1) that controls for only county and year fixed effects. We find that implementation of a ban on trans fat reduces CVD mortality rates by about 9% (see column 1). In column 2, we control for unemployment rates and (log) personal income per capita. In line with Ruhm (2000 Ruhm ( , 2003 , we find evidence of a procyclical relationship between economic conditions as measured by unemployment rates and personal income and CVD mortality rates. However, adding controls for measures of economic conditions only slightly increases (in absolute magnitude) the coefficient estimates of the trans fat ban effects. In column 3, we account for the structural break in CVD mortality rates caused by hospital-level interventions that affected mortality statistics in 2010-2012 in NYC by controlling for a dummy variable for NYC interacted with a dummy variable for the years 2010-2012. We find evidence suggesting that the NYC hospital-level interventions causes us to overestimate the impact of trans fat bans by about 30%, but the estimate of the CVD-related mortality reduction (about 7%) of trans fat bans remains statistically and economically significant.
We also want to rule out the possibility that we could be over-or under-estimating the treatment effect due to slow-moving trends (e.g. demographic changes or dietary habits) that may vary across counties. We examine this by adding to the regression model a linear time trend, which is allowed to vary according to whether a county implemented a trans fat ban in restaurants over the sample period. Controlling for a time trend specific to the treatment group reduces the coefficient associated with the trans fat ban dummy to about 6% (column 4). We present the estimates of our preferred specification in column 5. Here, we control for a county-specific linear time trend instead of a treatment-group-specific one. We find that trans fat bans reduce CVD mortality rates by about 4%, which implies that implementation of a ban on trans fat reduces CVD-related mortality by about 12 per 100,000
persons.
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In Appendix Table 3 , we show the results from an alternative way of addressing the hospital-level interventions in NYC. In particular, we find that restricting the analysis sample to the period over which CVD mortality rates Thus, we proceed with using our preferred specification (column 5 in Table 2) throughout the remainder of the main analysis.
In Table 3 , we analyze the impact of trans fat bans on the major components of CVD-related mortality. The magnitudes of the estimated effect of the trans fat ban on deaths caused by diseases of the heart and strokes are both negative and quantitatively important. Column 1 reproduces the estimate shown in column 5 of Table 2 . The estimate shown in column 2 of Table 3 implies that implementation of a ban on trans fat in restaurants decreases deaths attributed to heart disease by about 10 per 100,000 persons, and the corresponding estimated reduction in deaths attributed to strokes is about 3 per 100,000 persons. Thus, about 80% of the impact of trans fat bans on CVD is attributable to diseases of the heart, and the remainder is due to cerebrovascular diseases.
A natural question that comes to mind is whether the mortality reductions caused by trans fat bans are driven by the oldest segment of the population, since the risk of developing CVD increases with age, and thus those at the highest risk of dying from CVD-related health conditions are older individuals. The public-use mortality files provided by the NYS Department of Health do not disaggregate mortality data by cause of death, county of residence, and age group, but they do disaggregate all deaths by county of residence and age group. In Appendix Table 4 , we estimate the impact of trans fat bans on all-cause mortality rates for the following age groups: 0-24, 25-44, 45-64, and 65 and over. The estimated impacts for the younger three age groups are all statistically insignificant and are small in magnitude. In contrast, we find that trans fat bans reduced all-cause mortality rates among senior citizens by about 2%, which implies a reduction of about 15 deaths per 100,000 persons. This estimated reduction is quite close to the one we found for CVD-related mortality (column 5 of Table 2 ). These results suggest that trans fat bans reduce mortality among senior citizens and not younger individuals, and most of the reduction in all-cause mortality is driven by a reduction in CVD mortality rates. In the next section, we will also investigate whether trans fat bans impact other causes of death.
c. Robustness Checks
We conduct a variety of robustness checks relating to spillover effects, the timing of the financial crisis and the implementation of the trans fat bans, as well as model specification. We also examine whether trans fat bans affected CVD-related morbidity, as well as unrelated mortality outcomes. oils that are free of trans fat to oils that contain trans fat (Bordi et al. 2007a (Bordi et al. , 2007b . These spillover effects are most likely an issue in the case of counties that are immediately adjacent to treatment counties, so we examine whether omitting neighboring counties affects our results. When we do this, we find that the coefficient estimate on the trans fat ban dummy only slightly increases in magnitude (in absolute value), suggesting that treatment spillovers are not a major cause for concern in our analysis (row 1 of Table 4 ).
Second, since implementation of trans fat bans in restaurants coincided with the time period spanning the financial crisis, we address the concern that CVD mortality rates may have been differentially affected by economic conditions in treatment and control counties. We examine this possibility by allowing county unemployment rates and personal income per capita to have county-specific effects in the regression model. We find that the estimated impact of a ban on trans fat is little changed when we do this (row 2 of Table   4 ), suggesting that policy timing and the financial crisis are unlikely to account for our results.
Third, we assess the robustness of our results to a battery of specification checks. We have applied equal weights to each observation in our regression models throughout the analysis, so we test the sensitivity of our results to weighting the observations with the square root of a county's population. Row 3 of Table 4 shows that this weighting procedure produces smaller estimates than when we apply equal weights to all observations, but the results remain economically important and statistically significant.
Throughout the analysis we have used crude mortality rates, so we test the sensitivity of our estimates to using age-sex-adjusted CVD mortality rates to account for differences in the age and sex distributions across counties. We show that accounting for the age and sex structures of the county populations only slightly reduces the estimated effect of trans fat bans (row 4 of Table 4 ).
18
Using CVD mortality rates in levels (instead of in logs as in the main analysis) as a dependent variable produces an estimate for the reduction in CVD-related mortality (row 5 of Table 4 ) that is very close to the one calculated using the results from the main regression model shown in column 5 of Table 2 .
Because the data we use in our analysis are based on mortality counts, we also examine whether using poisson and negative binomial regressions produces similar results, and rows 6 and 7 of Table 4 show that they do: exponentiating poisson and negative binomial regression coefficients provide incidence rate ratios indicating that trans fat bans reduce CVD mortality rates by about 3%.
Fourth, mortality is an extreme health event and not all CVD-related events are fatal. We analyze the impact of trans fat bans on hospitalizations,
18 These age-sex-adjusted CVD mortality rates were standardized using the age-sex distribution from the United States 2000 Census.
which also include non-fatal events. We obtained data on CVD-related hospitalizations from the NYS Department of Health, but there is an important caveat with this part of the analysis. The mortality data are based on the deceased's county of residence whereas the hospitalization data are based on the county where the hospitalization took place. These data are not ideal because exposure to the treatment resulting from the policy is likely to be greatest in an individual's county of residence and we cannot observe the commuting patterns. Nonetheless, using our preferred specification, in row 8
of Lastly, we analyze the impact of trans fat bans in restaurants on major causes of death, some of which are unlikely to be affected by changes in the amount of trans fat in restaurant food. A caveat here is that our mortality data reflect the underlying or main cause of death, and any one single death is often attributed to multiple causes. Thus, we grouped the mortality outcomes according to the likelihood that the mortality outcome is linked to the consumption of trans fat, either directly based on medical research or because a mortality outcome has been strongly associated with cardiovascular health.
In particular, we grouped together CVD, diabetes, cancer, and pneumonia. The first three have been shown to be associated with trans fat consumption in the medical literature (Mozaffarian et al., 2006) . And there is evidence in the In contrast, in Panel B, we find that in addition to CVD, two other models produce statistically significant reductions in mortality, namely, those in which diabetes and pneumonia mortality rates are dependent variables. (We can strongly reject the null hypothesis that the estimates in Panel B are jointly equal to zero.) The specification involving diabetes is interesting because the medical community has found weak evidence that trans fat consumption increases the risk of diabetes (Mozaffarian et al., 2006) . It has also found similarly weak evidence that the consumption of trans fat raises the risk of developing some cancer. We find that the impact of trans fat bans on cancer mortality rates is negative, but the estimate is not statistically significant at conventional levels. Finally, the estimated impact on pneumonia mortality rates may stem from a bi-directional association between pneumonia and cardiovascular health (Corrales-Medina et al., 2013) .
In sum, we find that trans fat bans reduce CVD mortality rates and a few non-CVD-related mortality outcomes. Evidence from the medical community provides plausible mechanisms through which these latter effects might operate. However, relative to the estimated reduction per 100,000
persons, the largest impact of trans fat bans on mortality is for the outcome that is most strongly linked to the consumption of artificial trans fat, namely, CVD-related mortality.
d. Heterogeneous Impacts
Next, we address the question of heterogeneous treatment effects and, to save space, this section is coupled with an analysis that shows that our results are not driven by the composition of the control group.
Despite the fact that Figure 1 showed that treatment and control counties had similar trends in CVD mortality rates prior to the period over which trans fat bans were implemented, there may be a lingering concern about the comparability of the treatment and control counties. Table 5, we show results from analyses that examine the sensitivity of the results to changing the composition of the control group. Using the ERS metropolitan county classification system, we re-estimated our preferred specification using only metropolitan control counties (column 2) as well as using only nonmetropolitan counties (column 3). The estimated effects are nearly identical and very close to the estimated impact we found in the main analysis (reproduced in column 1).
Most of the treatment counties in our sample are part of the NYS Metropolitan Area. One might argue that a more appropriate control group would consist of counties that are also a part of the NYS Metropolitan Area.
To examine whether our results are sensitive to limiting the analysis sample to counties that belong to the NYS Metropolitan Area, we used supplementary data from the CDC Wonder database. 20 Using our preferred specification, analysis of this sample reveals that trans fat bans reduce CVD mortality rates by about 3.5% (column 2 of Panel B of Table 5 ), which is statistically significant at the 10% level. Again, this estimate is very similar in magnitude to the one we obtained in the main analysis. Overall, the analysis indicates that our results are robust to changes in the composition of the control group.
It is important to know whether a subset of the treatment counties is driving the results. For example, one might argue that NYC is a special case,
given that it is often at the frontier of the health policy arena, so we drop all observations from NYC from the analysis. Panel A of Table 5 (columns 4, 5, and 6) and Panel B of Table 5 (column 5) show that the average estimated impact of trans fat bans on CVD mortality rates ranges between about 3.3%
and 5.6%, with two of these estimates being statistically significant at the 10% level. However, estimates from models that include and exclude NYC observations are not statistically different from each other. For example, in Panel A, we fail to reject the null hypothesis that the estimates in column 1 (includes NYC observations) are equal to the estimates in column 4 (excludes NYC observations) with a p-value of 0.817. 21 Thus, overall, our results are robust to the concern that NYC drives impact of trans fat bans on CVD mortality rates.
Finally, we might expect heterogeneity in the effect of trans fat bans due to, for example, different pre-regulation levels of artificial trans fat in the local food supply. We examined this explicitly by estimating our preferred 20 The latest year for which mortality information is available is 2011, so the sample period for this analysis is 2002-2011. In addition to the NYS jurisdictions that are in the NYS metropolitan area (see Appendix Table 1 ), Stamford, CT, which is in Fairfield County, CT, also implemented a trans fat ban over the sample period. In 2008, Stamford, CT implemented a law that is comparable to the second phase of the NYS county laws.
specification on the main analysis sample, using all the control counties and only one treatment county at a time. Figure 2 summarizes the results from these regressions, which suggests that the impact of the laws varies by county.
While most estimates are negative in sign, we cannot reject the null hypothesis that the impact of trans fat bans on CVD mortality rates is zero for Albany, Nassau, Queens, Suffolk, and Westchester counties. However, we do find statistically significant and economically important reductions in CVD mortality rates for Bronx, Broome, Kings, New York, Richmond, and Rockland counties. Note that two of these counties are not NYC counties. This finding adds further empirical support for the conclusion we made above that the inclusion of NYC observations does not drive all of our main results.
e. Health Behaviors and other Policy Endogeneity Concerns
We now turn to analyzing the importance of changes in health-related behaviors that may be driving our results. A ban on trans fat can affect health and mortality risk through improvements in health-related behaviors. Major risk factors for CVD include unhealthy eating habits, lack of physical activity, smoking, and excessive alcohol consumption. In Table 7 , we show results from an analysis that is similar to our preferred specification, except that we use county-level obesity rates (a proxy for diet-related behavioral change), physical activity rates in the past month, current smoking rates, and drinking rates in the past month as dependent variables. We cannot reject the null hypothesis that the impact of trans fat bans on these health-related behaviors is zero. Thus, it does not appear to be the case that changes in these major CVD risk factors explain the impact of trans fat bans on CVD mortality rates. 22 This suggests that other behaviors associated with cardiovascular health, such as 22 In an unreported analysis, we also examined whether changes in health-related behaviors explain the mortality reductions caused by trans fat bans by directly controlling for them in CVD mortality regressions. Neither controlling for each one of these variables individually nor controlling for them all at once reveal any evidence that changes in health-related behaviors are driving our results. Coefficients on the trans fat ban dummy are unchanged when controlling for each individually or all behaviors simultaneously.
various dimensions of food consumption, might be important channels underlying the CVD mortality reductions. To our knowledge, detailed food consumption data by county over time do not exist, so we are unable to determine and rank the importance of a myriad of channels related to food consumption that could underlie the policy's effect on CVD mortality rates.
The policy's effect may be a result of a combination of several factors, such as changes in trans fat content in food away from home, changes in the quantity of food consumed away from home, and other changes in the quality of food offered by food service establishments.
A remaining policy endogeneity concern is that many counties that implemented bans on trans fat in restaurants also implemented menu labeling laws, which require chain restaurants to post calorie counts on menus. It is important to note, however, that while trans fat bans applied to all restaurants, only chains with 15 or more locations nationwide were required to comply with menu labeling laws. Nonetheless, Restrepo (2014) finds evidence that implementation of menu labeling laws caused a reduction in the probability of obesity and, since obesity is a risk factor for CVD-related disease, both trans fat bans and menu labeling laws could have independent effects on mortality.
In an unreported analysis, we controlled for obesity rates in CVD mortality regressions, and found that trans fat ban estimates were virtually identical with (coefficient -0.042, standard error 0.019) and without controls for obesity rates (coefficient -0.043, standard error 0.019). This suggests that changes in obesity rates following menu labelling laws are not the driving the impacts we find of trans fat bans on CVD mortality rates. Fortunately, two counties in our sample, Broome and Rockland, implemented trans fat bans but did not implement menu labeling laws, which allows us to shed more light on this policy endogeneity concern. In the analysis summarized in Figure 2 , we found economically important and statistically significant reductions in CVD mortality rates in Broome and Rockland counties. Thus, overall, the analysis indicates that policy endogeneity due to the similar timing in the rollout of trans fat bans and menu labeling laws is unlikely to account for our main results.
f. Dynamics of the Treatment Effect
Thus far, we have focused on the contemporaneous effect of a ban on trans fat in restaurant food on CVD-related mortality. However, a reduction in trans fat consumption may also have lagged effects on mortality rates if, for example, the cardiovascular health benefits of reduced trans fat consumption grow over time. Over our study period, a ban on trans fat was effective for at least two years for all but one county (see Appendix Table 1 ), so we estimate a model allowing for one lag. Leads of the trans fat ban variable are also included in the model to examine whether there is evidence that the treatment effects anticipate implementation of the policy mandate.
Here, it is necessary to distinguish between the Phase I and Phase II implementation dates to account for the different lag structures of the counties that implemented a ban on trans fat in one phase and the counties that did so over two phases. We also drop all NYC observations from the NYC hospitalintervention period to avoid confounding the lagged estimated effect of the trans fat ban with the hospital-level interventions.
In column 1 of Table 8 , we show results from a model that is comparable to the specification in column 5 of Table 2 . As in Table 2 , we find that trans fat bans contemporaneously reduce CVD mortality rates, with Phase II of the ban having a larger estimated impact than Phase I. The estimates, however, are not statistically different from each other (p-value 0.216). In column 2, we show estimates from a model including the leads and lag of the trans fat ban variable. The leads are not statistically significant, and F-tests of joint significance allow us to fail to reject the null hypothesis that the leads are jointly equal to zero. In contrast, we reject the null hypothesis that the contemporaneous and lagged effects are jointly equal to zero. In sum, these results imply that trans fat bans affect CVD-mortality quickly after implementation, and their effects may accumulate over time.
V.
Discussion
Plausibility of the Size of the Estimated Reduction in CVD
We have found strong evidence that trans fat bans in restaurants caused a reduction in mortality attributable to diseases of the heart and stroke. Is the size of the mortality effect we estimate in line with predictions based on evidence from the medical literature? Below, we perform a back-of-the envelope calculation to examine the plausibility of our estimates, which is based on several assumptions.
First, assume that the estimates in Angell et al. (2012) of the reduction in the amount of trans fat per purchase (2.4g) caused by trans fat bans in NYC fast food chains also applies to all food service establishments in all NYS counties that implemented trans fat bans. In the U.S., about one-third of daily calories (or about 1 out of 3 meals) come from food consumed away from home (Lin and Guthrie, 2012) . Thus, trans fat bans would reduce the consumption of trans fat from food service establishments by 2.4g, which is a reduction of about 1.08% of energy intake for individuals on a 2000-calorie daily diet (2.4g*9 calories ÷ 2000). 23 The FDA estimates that a 0.04% decrease in energy intake from trans fat would prevent between 240 and 480 fatal heart attacks nationally every year (FDA, 2003) . Thus, a 1.08% reduction in energy intake from trans fat is estimated to prevent between 6,480 and 12,960 fatal heart attacks per year. In 2006, NYS accounted for about 8% of all U.S. deaths attributable to heart disease. 24 Thus, our rough calculation implies that we might expect the reduction in trans fat intake from food 23 Stender and Dyerberg (2006) show that when it comes to fast food "it is possible to consume 10 to 25 g of these trans fatty acids in one day and for habitual consumers of large amounts of this food to have an average daily intake far above 5 g." Thus, the reduction in trans fat intake is likely to be much larger for certain individuals.
service establishments to prevent between 518 to 1,037 deaths due to heart disease in NYS.
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In column 2 of Table 3 , our 95% confidence interval of the estimated reduction in mortality due to heart disease is [-0.069 , -0.007], which implies that, on average, a NYS county-level trans fat ban reduces mortality by between 2 and 17 per 100,000 persons. 26 Given that NYS had 50,470 heartdisease-related deaths in 2006, we estimate that, on average, statewide implementation of trans fat bans would save between 353 and 3,482 lives per year.
There are three important points to bear in mind before comparing the two ranges above. First, our regression estimate captures the impact of a trans fat ban on mortality caused by heart disease that may operate through a variety of channels, not only through reduced trans fat intake from food away from home. For example, it may also capture the mortality impact operating through dietary changes made in response to increased awareness of the harmful consequences of consuming artificial trans fats. Second, changes in the amount artificial trans fat in NYC fast food chains after bans on trans fat were implemented may not be representative of corresponding changes in fast food chains in other areas of NYS, let alone the fact that fast food chains may not be representative of all food service establishments. Third, the FDA's estimates of the heart disease mortality impact of reducing trans fat consumption are based on medical evidence that trans fat consumption increases the risk of developing heart disease because trans fat increases LDLto-HDL cholesterol levels. However, Mozaffarian et al. (2006) indicate that trans fat consumption also influences other risk factors for CVD. Thus, the 25 If we instead assume that the mortality impact is equal across states, the corresponding range of prevented deaths in NYS that we might expect is between 130 and 259. This is also within our range of estimates of the impact of a trans fat ban on mortality caused by coronary heart disease. FDA's estimates of the mortality impact of a reduction in trans fat intake may underestimate the total impact of trans fat intake on heart disease mortality.
Despite these caveats, it is comforting that the mortality impacts in NYS that we obtained from the rough calculation above are within our range of estimated mortality impacts.
Another way to assess the plausibility of our estimated mortality reductions is to compare them to the mortality reductions caused by statin medication therapy. In a meta-analysis of 164 randomized placebo-controlled trials, Law et al. (2003) find that a daily intake of statins lowered LDL cholesterol levels by 1.8 mmol/l and 58 randomized trials revealed that a 1 mmol/l reduction in LDL cholesterol resulted in an 11% reduction in fatal heart disease events in the first year. In a meta-analysis of controlled dietary trials, Mozaffarian et al. (2006) find that substituting 1% of dietary energy from unsaturated fats with trans fat increases LDL by between 0.04 and 0.07 mmol/l. Assuming that trans fat bans also caused a substitution towards unsaturated fats equal to 1% of dietary energy implies a reduction in fatal heart disease events of about 0.44% to 0.77%, which is in line with the lower end of our 95% confidence interval. However, again, trans fat intake affects cardiovascular health through channels other than increases in LDL cholesterol (Mozaffarian et al., 2006) , e.g. they promote inflammation, so this back-of-the-envelope calculation may account for only part of the policy's effect on cardiovascular health.
Are Trans Fat Bans a Cost-Effective Policy?
The financial costs associated with trans fat bans include all the costs related to compliance including substituting PHOs with healthier oils, creating new recipes without PHOs, training food preparers to cook without PHOs, etc.
There is also a loss in consumer surplus if consumers value foods containing artificial trans fats because of taste or cost concerns. Higher food production and service costs would be passed on to consumers in the form of higher prices. We do not have information on the price of food away from home by county over time, 27 but we conduct a rough cost-benefit analysis to assess whether trans fat bans would be welfare improving if they were implemented in all NYS counties.
To Restaurant Association (NRA) estimates that the cost of food and drinks amounts to one-third of sales. 28 Existing evidences indicates that the cost of going trans fat free is small (e.g. Lueck and Severson, 2006; Tan, 2009) meals, then the consumer "taste costs" should not be larger than $0.08 per meal.
The maximum cost to consumers to break even seems small, however, existing evidence underlines that consumers do not place a very high value on consuming artificial trans fat. For example, Doell et al. (2012) (Bordi et al. 2007b) .
In sum, the potential benefits are quite large relative to the financial costs of implementing bans on artificial trans fat. The loss in consumer surplus would have to be much larger than the financial costs to outweigh the benefits in terms of monetized mortality reductions. The food service industry has an incentive to improve any loss in flavor associated with substituting PHOs with healthier oils, so taste costs, even if they are large at the outset, are likely to diminish over time.
VI. Conclusion
We have exploited plausibly exogenous variation in artificial trans fat content in restaurants due to the implementation of trans fat bans in some counties in New York State to examine whether it affects mortality due to cardiovascular diseases (CVD) in a "difference-in-difference" empirical framework. The results indicate that harmful macronutrients with no established health benefits such as artificial trans fats can have significant repercussions on population health and longevity. In particular, we have shown that artificial trans fat consumption has a strong impact on mortality caused by heart disease and stroke. The estimated mortality impacts of banning trans fat in restaurant food are economically important, and the range of effect sizes overlaps with predictions by the public health and medical communities. We find that CVD mortality rates responded within a year after the implementation of trans fat bans, and patterns in the data indicate that the number of prevented CVD-related deaths may increase in the years to come.
There are several avenues for further research. First, we cannot separately identify the effect of eliminating artificial trans fats from substituting for healthier fats. The health benefits of reducing the amount of artificial trans fat in food away from home is likely to highly depend on the type of substitution behavior followed by restaurants. Analysis of detailed restaurant-level data sets would be useful to shed light on these issues. Second, the analysis could be enriched by using survey data on CVD-related health conditions, cholesterol levels, and dietary habits and patterns of eating away from home. These data would allow a detailed investigation of some of the channels and heterogeneities that might underlie the mortality impacts we have estimated in this study.
Reducing the amount of artificial trans fat in restaurant food appears to be cost-effective way of improving diets on a large scale. However, bans on trans fat should be considered a complement to rather than a substitute for other ways of promoting healthier behaviors. Trans fat consumption is only one of the many risk factors associated with CVD, many of which are behavioral. That said, our evidence does indicate that even small changes in the quality of macronutrients can lead to significant improvements in population health. Note: Covariates include the county level unemployment rate and log personal income per capita, and a dummy for NYC interacted with a dummy for years 2010-2012.
Sample size is 682. Standard errors are clustered at the county level, and are in parentheses below OLS coefficients. *,**, and *** denote statistical significance at the 10%, 5%, and 1% level, respectively. Note: Estimates from seemingly unrelated regressions model. Covariates include the county level unemployment rate and log personal income per capita, and a dummy for NYC interacted with a dummy for years 2010-2012. Sample size is 682. Standard errors are clustered at the county level, and are in parentheses below coefficients. *,**, and *** denote statistical significance at the 10%, 5%, and 1% level, respectively. Note: Covariates include the county level unemployment rate and log personal income per capita. Sample size is 469. Standard errors are clustered at the county level, and are in parentheses below OLS coefficients. *,**, and *** denote statistical significance at the 10%, 5%, and 1% level, respectively. Note: Covariates include the county level unemployment rate and log personal income per capita. Sample size is 667. Note that the sample size is lower because we drop 2010 observations from 4/5 NYC counties and all NYC observations from 2011-2012. Standard errors are clustered at the county level, and are in parentheses below OLS coefficients. *,**, and *** denote statistical significance at the 10%, 5%, and 1% level, respectively. No cooking oils, shortenings or margarines can be used for frying that contain ≥ 0.5g of artificial trans fat Note: Phase I bans the use of partially hydrogenated vegetable oils (PHVO), shortenings, and margarines for frying, grilling or as spread unless the manufacturer's label shows that it contains < 0.5g of artificial trans fat per serving. The use of trans fat-containing oils and shortenings for deep frying cake batter and yeast dough was allowed until Phase II. Phase II prohibits storing, using, or serving any food item containing PHVO oils, shortenings, or margarines if it contains more than or equal to 0.5g of artifical trans fat per serving. Note: Covariates include the county level unemployment rate and log personal income per capita. Standard errors are clustered at the county level, and are in parentheses below OLS coefficients. *,**, and *** denote statistical significance at the 10%, 5%, and 1% level, respectively.
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